Zealand Pharma A/S (OTCMKTS:ZLDPF) Issues Earnings Results

Zealand Pharma A/S (OTCMKTS:ZLDPF) announced its earnings results on Thursday. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.19, Zacks reports. Zealand Pharma A/S had a negative return on equity of 18.49% and a negative net margin of 1,375.16%.

Zealand Pharma A/S Stock Performance

OTCMKTS:ZLDPF opened at $108.30 on Friday. The company has a fifty day simple moving average of $102.06 and a two-hundred day simple moving average of $113.67. The company has a market cap of $7.69 billion, a price-to-earnings ratio of -44.57 and a beta of 0.88. The company has a quick ratio of 35.49, a current ratio of 35.49 and a debt-to-equity ratio of 0.03. Zealand Pharma A/S has a 52 week low of $67.58 and a 52 week high of $141.74.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. JPMorgan Chase & Co. assumed coverage on Zealand Pharma A/S in a research report on Friday, November 8th. They issued an “overweight” rating on the stock. Cantor Fitzgerald raised Zealand Pharma A/S to a “strong-buy” rating in a research report on Tuesday, January 21st.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.